Skip to content

Andarix Pharmaceuticals to Present at Neosynth Breast Cancer Conference

Targeted therapy for breast cancer is based on personalized medicine approach

SOMERVILLE, MA — April 24, 2019— Andarix Pharmaceuticals, a leader in the
discovery and development of targeted peptide therapy for cancer announced today that
it will present at the Neosynth Breast Cancer Conference in Boston MA on April 24-25th
2019.
The presentation will address the ability of theranostic technology to provide
personalized medicine to diagnose and treat breast cancer. The three main types of
breast cancer are defined by specific biomarkers and are over-expressed in the disease.
The Andarix drug Tozaride targets somatostatin receptors on breast cancer cells and
represents a new target for breast cancer therapy. The company will present clinical
data to support the biomarker application.

About Tozaride
Tozaride is a novel, best-in-class cancer therapy based on a radio-labeled somatostatin
peptide analogue. Early clinical studies of Tozaride demonstrated that it is well tolerated
and may produce prolonged stable disease and improved overall survival in advanced
lung cancer patients whose disease has continued to progress after failing other
therapies. Tozaride targeted radiotherapy represents a new treatment paradigm which is
expected to yield significant clinical benefit for both lung cancer (SCLC, NSCLC), and
pancreatic cancer patients. Along with its companion diagnostic that helps identify
patients most likely to respond – those with enough expression of the peptide’s target –
Tozaride could provide another treatment option for patients who are not eligible for, or
who have not responded to current therapies.

About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer,
developing both the imaging agents that can identify appropriate patients, as well as the
targeted therapies for these patients. The company’s products have progressed through
early clinical development. The Andarix technology is based on a proprietary
somatostatin peptide conjugate applicable to lung, pancreatic, neuroendocrine, and
other cancers. Extensive research has demonstrated that somatostatin receptors are
highly up-regulated on several solid tumors, particularly lung, neuroendocrine, and
pancreatic tumors. To learn more about Andarix, please visit www.andarix.com .

Contact:
Andarix Pharmaceuticals
617-957-9858
info@andarix.com

Leave a Comment